Scientific literature shows that the use of TEG technology can help clinicians to improve patient outcomes and reduce costs by analyzing the coagulation state of a blood sample (11-12). By individualizing goal-directed coagulation management, it is possible to reduce inappropriate blood transfusions (7-9), and stratify patients according to their risk of bleeding and/or thrombotic complications (3, 10, 13-15). There is consequently a great opportunity to achieve substantial cost savings with a goal-directed TEG program (10-11).
Blood Product Use
The overall goal of the TEG® system is to reduce the use of unnecessary blood products and reduce thrombotic complications leading to improved patient outcomes.
Using the TEG system to monitor a patient’s hemostasis during surgery allows for a reduction in blood product usage by providing clinicians with information to help determine which specific blood products are needed to stop bleeding, and accurately identifies the need for re-operations by ruling out a coagulopathic cause of bleeding (7-12).
Identifying inhibitions in platelet function can provide important information to help the clinician assess bleeding and ischemic events.
Anticoagulant or antiplatelet therapy is often stopped a few days before cardiovascular surgery to reduce the risk of perioperative bleeding while potentially increasing the risk of a thromboembolic event in the preoperative period.
TEG® PlateletMapping® assays can be used to assess platelet function and inhibition post-operatively or after percutaneous coronary intervention (PCI) (6, 10, 13-15).